AI summary · may contain errors
Nirsevimab reduced RSV hospitalization risk by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) through 180 days post-receipt in 4,826 infants.
- Open access
Moving in medRxiv, Clinical Infectious Diseases, bioRxiv, JAMA, JAMA Pediatrics, Journal of Allergy and Clinical Immunology, The Lancet Infectious Diseases and American Journal of Respiratory and Critical Care Medicine.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Nirsevimab reduced RSV hospitalization risk by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) through 180 days post-receipt in 4,826 infants.
AI summary · may contain errors
SARS-CoV-2 shows different clade and mutation patterns between community and clinical surveillance in Washington State, with Delta (21J) and BA.1 (21K) more common in community samples.
AI summary · may contain errors
In adults with lung or kidney transplant, two doses of AS01(E)-adjuvanted RSVPreF3 increased RSV-A and RSV-B neutralizing titers after dose 2 by 1.34 and 1.26, respectively.
AI summary · may contain errors
Higher weekly levels of specific respiratory viruses were linked to increased stroke admission rates in Victoria, Australia, with attributable fractions of 4.6% for enterovirus and 1.3% for human metapneumovirus.
AI summary · may contain errors
Intranasal VIP-N+circRNA vaccination in mice encoding RSV pre-F elicits the strongest neutralizing activity and cross-protection against RSV-A and RSV-B, significantly reducing pulmonary viral burden and lung inflammation.
AI summary · may contain errors
Nirsevimab is associated with lower RSV-LRTI-related hospitalization rates in French infants during the first year after the 2023 and 2024 immunization campaigns, with effectiveness of 66% and 72%.
AI summary · may contain errors
In preschool children with severe treatment-refractory wheeze, indolent rhinovirus infection is linked to higher BAL eosinophil-derived neurotoxin (EDN) concentrations, not increased intact eosinophils.
AI summary · may contain errors
Recombinant CC16 reduces RV-A1B viral burden in human nasal epithelial cells, and CC16-deficient mice show worse RV infection with lower lung host-defense factor expression.
AI summary · may contain errors
Maternal RSVpreF vaccination in pregnant individuals in Australia is linked to 77.8% effectiveness against RSV-LRTD hospitalization in infants from birth through 6 months.
AI summary · may contain errors
RSV vaccination in US Medicare fee-for-service nursing home residents was associated with 73% vaccine effectiveness against RSV-associated hospitalization during the first season.
AI summary · may contain errors
Broad computable phenotypes for RSV, influenza, and COVID-19 in English EHRs (Sep 2016–Aug 2024) increased misclassification risk for mild cases versus narrow phenotypes.
AI summary · may contain errors
Influenza virus nucleoprotein (NP) antagonizes RIG-I activation by host RNA polymerase III–transcribed non-coding RNAs, linked to suppressed viral replication.
AI summary · may contain errors
In 1052 children aged 2–59 months hospitalized with WHO-defined severe community-acquired pneumonia in the PediCAP trial, no risk score clearly outperformed WHO criteria for in-hospital mortality (ROC-AUC ~0.73–0.87).
AI summary · may contain errors
In a multicenter cohort of 819 pediatric allogeneic hematopoietic cell transplant recipients, proven or probable human adenovirus disease occurred in 10.9% overall and 12.6% under surveillance.
AI summary · may contain errors
mRNA-1345 vaccination induces comparable RSV-specific CD4+ T cell responses in younger and older adults, with CD4+ responses persisting for 24 months.
Journals this month
Topics moving, week to 17 Nov 2026
By field